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Simple Summary: The majority of breast cancers express the estrogen receptor alpha (ERα).
This receptor is of central importance for breast cancer development and tumor outgrowth,
and represents an important target for therapeutic intervention. However, the molecular mechanisms
that are responsible for the control of ERα expression and function in the context of breast cancer
initiation and progression are complex and yet not fully understood. Here we demonstrate that
RASSF1A acts as an inhibitor of ERα-driven breast cancer cell growth through a complex, hierarchically
organized network that initially involves suppression of the Hippo effector Yes-associated protein 1
(YAP1), which is followed by inhibition of AKT1 activity, increased FOXO3A activity as well as a
blockade of FOXM1 and ERα expression. Together our findings provide important new mechanistic
insights into how the loss of RASSF1A contributes to ERα+ breast cancer initiation and progression.
Abstract: The estrogen receptor alpha (ERα) is expressed by the majority of breast cancers and plays
an important role in breast cancer development and tumor outgrowth. Although ERα is well known
to be a specific and efficient therapeutic target, the molecular mechanisms that are responsible for
the control of ERα expression and function in the context of breast cancer initiation and progression
are complex and not completely elucidated. In previous work, we have demonstrated that the
tumor suppressor RASSF1A inhibits ERα expression and function in ERα-positive breast cancer cells
through an AKT-dependent mechanism. Transcriptional activators such as forkhead box protein M1
(FOXM1) and forkhead transcription factor 3A (FOXO3A) and signaling pathways such as the Hippo
pathway are also known to modulate ERα expression and activity. Here we report that RASSF1A acts
as an inhibitor of ERα-driven breast cancer cell growth through a complex, hierarchically organized
network that initially involves suppression of the Hippo effector Yes-associated protein 1 (YAP1),
which is followed by inhibition of AKT1 activity, increased FOXO3A activity as well as a blockade of
FOXM1 and ERα expression. Together our findings provide important new mechanistic insights into
how the loss of RASSF1A contributes to ERα+ breast cancer initiation and progression.
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1. Introduction
Breast cancer is the most common tumor diagnosed among women, and it is the second leading
cause of cancer death worldwide [1]. Estrogen receptors (ER) are expressed in approximately 70%
of human breast cancers and play key roles in tumor development and treatment outcome in breast
cancer patients [2]. Identification of molecular mechanisms that regulate ER activity and function may
facilitate the development of improved breast cancer treatment regimes. However, the cellular and
molecular events that regulate ERα and ERβ protein expression and function are complex and not
fully elucidated.
The Ras associated domain family 1 isoform A (RASSF1A) is frequently inactivated in breast
carcinomas and is associated with estrogen receptor status because aberrant DNA methylation is
thought to inactivate RASSF1A more frequently in ER+ breast carcinomas [3,4]. These findings
prompted us to investigate a potential functional relationship between RASSF1A and ERα. In previous
studies we reported that reconstitution of RASSF1A in MCF7 cells led to decreased ERα levels and
reduced sensitivity to estrogen (E2), which was accompanied by induction of cell cycle arrest and
senescence [3]. Based on these findings we suggested that RASSF1A acts as a tumor suppressor in ERα+
breast epithelial cells, in part through inhibition of ERα expression and activity, as well as through
repression of signaling pathways that are important for E2 independence [3]. However, the molecular
mechanisms through which RASSF1A affects ERα expression and function, as well as other proteins
that might mediate the tumor-suppressive functions of RASSF1A in breast epithelial cells and during
breast cancer initiation remain to be fully elucidated.
The forkhead transcription factor (FOX) proteins are transcriptional regulators that play a central
role during development and adult tissue homeostasis [5]. FOXM1 and FOXO3A are two members of
this family that are essential components of oncogenic and tumor-suppressive pathways, respectively [5].
Accurate chronological and steric control of FOXO3A and FOXM1 expression regulates gene expression
networks that determine cell fate through the modulation of cell cycle progression, differentiation,
and survival [5]. Dysfunction in the regulation of their activity can cause tumor initiation, progression,
and resistance to therapy [5].
Phosphorylation of FOXO3A protein by AKT or the serine/threonine-protein kinase
serum/glucocorticoid-regulated kinase 1 (SGK1) sequesters the transcription factor in the cytoplasm,
leading to its destruction by the ubiquitylation-mediated proteasome pathway [6–9]. This impairs the
activation of FOXO3A-dependent tumor suppressive gene transcriptional programs. ERK and IKKβ
also phosphorylate FOXO3A, targeting the protein for degradation by mechanisms involving ubiquitin
E3 ligases, such as SKP2 and MDM2 [10–12]. In contrast, phosphorylation by AMP-activated protein
kinase (AMPK), mammalian Ste20-like kinase (Mst1), the Jun N-terminal (JNK), or p38 MAPKs promotes
the nuclear localization of the FOXO3A protein [13–15], thus enhancing its ability to transcriptionally
regulate proliferative arrest, differentiation, and cell death. Consequently, the deregulation of FOXO3A
and other FOX proteins through post-translational modification can directly contribute to tumor
initiation, progression, and therapy resistance [16–18].
FOXM1 and FOXO3A are decisive for ERα regulation in normal tissues, as well as during ER+
breast cancer initiation, progression, and the development of drug resistance [5]. FOXM1 expression is
activated by ERα in the presence of estrogens through direct binding of ERα to an estrogen-response
element site within the FOXM1 promoter [19], consistent with the observation that elevated expression
of FOXM1 in breast cancer strongly correlates with ERα expression [19,20]. Silencing of FOXM1
abolishes the E2-mediated proliferation of MCF7 cells [20], while ectopic expression of constitutively
active FOXM1 abrogates the growth arrest caused by tamoxifen [19]. These findings collectively suggest
that FOXM1 is an important regulator of the mitogenic functions of ERα and estrogen in breast tumor
cells and that deregulation of FOXM1 subsequently may contribute to anti-estrogen insensitivity [19].
The FOXO3A protein, on the other hand, interacts directly with ERα and ERβ, which inhibits their
transcriptional activities and thereby suppresses the expression of ER target genes [21]. Thus, FOXO3A
can act as a tumor suppressor [5] and is a downstream target of several oncogenic pathways [9],
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including the ERK [10], nuclear factor-kB (NF-kB)-inhibitor of NF-kB kinase-β (IKKβ) [11], and PI3K-Akt
signaling cascades [6–9]. Consistently, FOXO3A inhibits estrogen-dependent breast cancer proliferation
and suppresses tumorigenesis of MCF7 cells in an animal orthotopic breast tumor model, providing
compelling evidence that FOXO3A plays an important role in the suppression of estrogen-dependent
breast cancer [21]. Interestingly, FOXO3A is a functional antagonist of FOXM1 [5,22], and thus FOXO3A
could conceivably also be an inhibitor of ERα by counteracting FOXM1 activity.
As the silencing of FOXM1 abolishes the E2-mediated proliferation of MCF7 cells [20], and FOXO3A
can functionally antagonize FOXM1 [22], we hypothesized that RASSF1A may inhibit FOXM1.
Furthermore, RASSF1A inhibits AKT1 [3,23]. As AKT1 is an inhibitor of FOXO3A [6] and FOXO3A is an
inhibitor of ERα activity [21], we also hypothesized that RASSF1A may inhibit ERα through mechanisms
that involve activation of FOXO3A. Moreover, RASSF1A can activate the Hippo pathway [24,25] and
modify the function of the Hippo-kinase effector YAP1 [26]. YAP1 can activate AKT1 and Skp2 leading
to increased degradation of FOXO1/3 [27]. We therefore additionally hypothesized that RASSF1A may
inhibit AKT1 activity through a mechanism that involves changes in the YAP1 function.
Consistent with these hypotheses, we report here that RASSF1A reduces both FOXM1 and ERα
expression and increases FOXO3A activity. Knockdown of FOXM1 in ERα+ MCF7 breast cancer cells
led to reduced expression of ERα, cell cycle arrest, and senescence, partially phenocopying the effects of
ectopic RASSF1A expression in these cells. Partial knockdown of FOXO3A caused increased outgrowth
of colonies and reduced induction of senescence in the presence of RASSF1A in comparison to controls.
Knockdown of YAP1 in ERα+ MCF7 breast cancer cells led to reduced expression of ERα and FOXM1,
cell cycle arrest, and senescence and inhibition of AKT1 and increased activity of FOXO3A. Based on
these findings, we conclude that RASSF1A acts as an inhibitor of ERα expression and function through
a hierarchical mechanism that involves suppression of the Hippo kinase effector YAP1 and subsequent
inhibition of AKT1 activity, increased FOXO3A activity, as well as the blockade of FOXM1 expression
and activity.
2. Results
2.1. RASSF1A Causes Decreased Expression of FOXM1 and ERα, and Induces Senescence
As FOXM1 is an important regulator of the mitogenic functions of ERα in breast tumor cells,
we hypothesized that RASSF1A may exert some of its suppressive effects on ERα through regulating
FOXM1 expression and activity. In agreement with this hypothesis, induction of RASSF1A expression
in MCF7 cells that conditionally express RASSF1A upon addition of doxycycline (RASSF1A conditional
MCF7 cells) caused decreased expression of ERα and FOXM1 proteins, increased expression of the
cell cycle inhibitor p21Cip1/Waf1, and slightly increased expression of FOXO3A and correlated with the
induction of cellular senescence (Figure 1A). Further analysis using qPCR confirmed that following
RASSF1A induction, transcription of ERα and FOXM1 is reduced, whereas transcription of p21Cip1/Waf1
and FOXO3A is increased (Figure 1B). In addition, we also found that FOXM1 expression in MCF7
cells is dependent on E2 (Figure 1C), in accordance with previous reports [19]. Thus, inhibition of
endogenous FOXM1 by RASSF1A could be secondary at least in part to the downregulation of ERα
by RASSF1A.
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Figure 1. RASSF1A causes decreased expression of FOXM1 and ERα, and induces senescence. (A) 
Induction of RASSF1A expression in conditional RASSF1A MCF7 cells was achieved by culturing 
cells in the presence of 1 μg/mL doxycycline. Cell extracts from induced and non-induced conditional 
RASSF1A cells were prepared 48 h after doxycycline administration and were analyzed by 
immunoblotting using the indicated antibodies. Actin serves as a loading control (left panel). 
Densitometric quantification of the bands FOXO3A—doxycycline: 100 versus FOXO3A +doxycycline: 
173; detailed information about the western blots are given at Figure S1. Conditional RASSF1A cells 
were plated at equal densities and grown for 6 days in the presence or absence of doxycycline as 
indicated. RASSF1A-induced senescence was subsequently monitored by SAβ-gal staining (right 
panel). Bars = 100 μm. The quantification of senescent cells was achieved by counting (middle panel). 
Mean values ± s.d. of six independent experiments are shown. p-values < 0.05 are indicated by 
asterisks. (B) RASSF1A downregulates transcription of ERα and FOXM1 but increases the expression 
Figure 1. RASSF1A causes decreased expression of FOXM1 and ERα, and induces senescence.
(A) Induction of RASSF1A expression in conditional RASSF1A MCF7 cells was achieved by culturing
cells in the presence of 1 µg/mL doxycycline. Cell extracts from induced and non-induced
conditional RASSF1A cells were prepared 48 h after doxycycline administration and were analyzed
by immunoblotting using the indicated antibodies. Actin serves as a loading control (left panel).
Densitometric quantification of the bands FOXO3A—doxycycline: 100 versus FOXO3A +doxycycline:
173; detailed information about the western blots are given at Figure S1. Conditional RASSF1A cells
were plated at equal densities and grown for 6 days in the presence or absence of doxycycline as
indicated. RASSF1A-induced senescence was subsequently monitored by SAβ-gal staining (right panel).
Bars = 100 µm. The quantification of senescent cells was achieved by counting (middle panel).
Mean values ± s.d. of six independent experiments are shown. p-values < 0.05 are indicated by
asterisks. (B) RASSF1A downregulates transcription of ERα and FOXM1 but increases the expression
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of p21Cip1/Waf1 and FOXO3A. Conditional MCF7 cells were grown in the presence or absence of 1 µg/mL
doxycycline as indicated. mRNA was harvested 48 h after doxycycline administration. ERα, FOXM1,
p21Cip1/Waf1, and FOXO3A transcript levels were analyzed by quantitative PCR. Mean values ± s.d.
of four independent experiments are shown. p-values < 0.05 are indicated by asterisks. (C) FOXM1
expression in MCF7 cells is dependent on E2. Conditional MCF7 cells were grown in the presence
or absence of 1µg/mL doxycycline, and in the presence or absence of different E2 concentrations as
indicated. Cell extracts prepared 48 h after doxycycline administration and 24 h after E2 exposure
were analyzed by immunoblotting with the indicated antibodies. (D) Conditional RASSF1A MCF7
cells were grown in the presence or absence of 1 µg/mL doxycycline and in the presence or absence
of E2 as indicated. mRNA was harvested 48 h after doxycycline administration and 24 h after E2
exposure. Transcript levels of the indicated genes were analyzed by quantitative PCR. RASSF1A caused
reduced expression of Cdk1, 2, and Plk1, whereas no significant reduction of Cdk4 and 6 and increased
expression of p21Cip1/Waf1 was observed. Similar results were obtained in the absence (left panel) and
the presence of E2 (right panel). Mean values ± s.d. of four independent experiments are shown.
p-values < 0.05 are indicated by asterisks.
FOXM1 activity is strongly dependent on posttranscriptional modifications such as
phosphorylation and acetylation [5]. FOXM1 includes phosphorylation sites that are targeted by
cell cycle-dependent kinases (Cdks) and Plk1 [5,28–32]. Phosphorylation of FOXM1 is important for
inhibition of autorepression [30], activation of mitotic progression [31], and inhibition of senescence [29].
Using qPCR, we found that RASSF1A induction caused decreased expression of Cdk1, 2, and Plk1
in RASSF1A conditional MCF7 cells whereas no inhibition of Cdk4 and 6 was observed (Figure 1D).
However, RASSF1A caused increased expression of p21Cip1/Waf1 (Figure 1D), as we have reported
previously [3]. Since p21Cip1/Waf1 binds to Cdk4 and 6 and thereby blocks their activity [33], we conclude
that RASSF1A might inhibit Cdk4 and 6 in an indirect mechanism by increasing the expression
of p21Cip1/Waf1. In turn, this may regulate FOXM1 activity through regulatory phosphorylation.
Collectively, these observations suggest that RASSF1A has the potential to inhibit FOXM1 expression
and activity both transcriptionally and post-translationally.
2.2. Knockdown of FOXM1 Inhibits Expression of ERα and Induces Cell Cycle Arrest and Senescence,
Phenocopying the Effects of RASSF1A
The above findings suggest that RASSF1A-mediated inhibition of ERα+ breast cancer cell growth
may involve inhibition of FOXM1 expression. To determine whether loss of FOXM1 expression
functionally phenocopies RASSF1A expression, we used stable knockdown of FOXM1 in parental
MCF7 cells. Reduced expression of FOXM1 was verified by immunoblotting (Figure 2A) and qPCR
(Figure 2B). Similar to induction of RASSF1A expression, knockdown of FOXM1 caused growth arrest
and cellular senescence (Figure 2A), and reduced expression of ERα while increasing expression of
p21Cip1/Waf1 and FOXO3A (Figure 2A,B). Taken together these observations are consistent with the
notion that suppression of FOXM1 expression by RASSF1A plays an important role in RASSF1A-induced
cell cycle arrest and senescence.




Figure 2. Knockdown of FOXM1 inhibits expression of ERα and induces cell cycle arrest and
senescence, phenocopying the effects of RASSF1A. (A) Stable knockdown of FOXM1 was performed
in parental MCF7 cells using shRNAs (FOXM1k.o.1 and FOXM1k.o.2). Cell extracts were prepared
48 h after lentiviral transduction. Western blots of lysates from the two independent FOXM1 shRNAs
(FOXM1k.o.1 and FOXM1k.o.2) in MCF7 cells were probed with the indicated antibodies. Actin served
as a loading control (upper left panel). Knockdown of FOXM1 using FOXM1k.o.1 and FOXM1k.o.2
in MCF7 cells induced growth inhibition and senescence as evidenced by SAβ-gal staining 48 h after
lentiviral transduction (lower panel). Bars = 100 µm. Quantification of the percentage of SAβ-gal
positive cells in two independent knockdowns of FOXM1 expression in MCF7 cells (FOXM1k.o.1
and FOXM1k.o.2) is presented as mean values ± s.d. of three independent experiments. p-values
< 0.05 are indicated by asterisks (upper right panel). (B) Knockdown of FOXM1 in MCF7 cells
using the shRNAs FOXM1k.o.1 and FOXM1k.o.2 was performed and mRNA was prepared 48 h after
lentiviral transduction. Transcript levels of the indicated genes were analyzed by quantitative PCR.
Mean values ± s.d. of three independent experiments are presented. p-values < 0.05 are indicated
by asterisks.
2.3. Ectopic Expression of FOXM1 Does Not Rescue Cells from RASSF1A-Mediated ERα Suppression and Cell
Cycle Arrest
As RASSF1A causes decreased expression of FOXM1 (Figure 1A), we next investigated whether
ectopic expression of FOXM1 is sufficient to rescue MCF7 cells from RASSF1A-mediated suppression
of ERα and growth arrest. Ectopic expression of FOXM1 in RASSF1A conditional MCF7 cells
neither abolished RASSF1A-mediated down-regulation of ERα expression (Figure 3A), nor inhibited
RASSF1A-induced growth arrest (Figure 3B). Unexpectedly, RASSF1A inhibited the ectopic expression
of the FOXM1 protein (Figure 3A). Under physiological conditions, inhibition of the proteasome
by Bortezomib causes reduced transcription of FOXM1 and ERα [34], leading to lower endogenous
levels of these proteins (Figure 3C left panel). In MCF7 cells ectopically expressing FOXM1 in the
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absence of RASSF1A, no decrease in FOXM1 protein levels was observed in the presence of Bortezomib
as expected due to ectopic expression being under the control of the CMV promoter. However,
RASSF1A expression reduced FOXM1 protein levels in both the presence and absence of Bortezomib
(Figure 3C right panel). Thus, RASSF1A decreases levels of ectopic FOXM1 protein independently of
proteasome-mediated destruction.
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Figure 3. Ectopic expression of F X 1 cannot rescue R SSF1 - ediated ERα suppression and cell
cycle arrest. (A) RASSF1A-inducible MCF7 cells were retrovirally transduced with a FOXM1 expression
vector or with an empty vector. Both cell lines were cultured in the presence or absence of 1 µg/mL
doxycycline as indicated. After 48 h cells were harvested and subsequently lysates were analyzed
by immunoblotting using the indicated antibodies. (B) Equal numbers of knockout and negative
control cells were grown in the presence or absence of 1 µg/mL doxycycline as indicated. After 14 days,
colonies were fixed at equal time points and counted. Mean values ± s.d. of four independent
experiments are presented. p-values < 0.05 are indicated by asterisks. (C) MCF7 cells were cultured in
the presence or absence of 25 nM Bortezomib. After 30 h cells were harvested and lysates were analyzed
by immunoblotting using the indicated antibodies (left panel). Conditional RASSF1A MCF7 cells were
grown in the presence or absence of 1 µg/mL doxycycline and in the presence or absence of Bortezomib
as indicated. Cells were harvested 48 h after doxycycline administration and 30 h after Bortezomib
exposure. Lysates were analyzed by immunoblotting using the indicated antibodies (right panel).
(D) Conditional RASSF1A MCF7 cells with ectopic FOXM1 expression were cultured in the presence or
absence of 1 µg/mL doxycycline as indicated and mRNA was prepared after 48 h. Transcript levels of
FOXM1 were analyzed by quantitative PCR. Transcript levels of endogenous FOXM1 from non-induced
empty vector-carrying conditional MCF7 cells were used to quantify ectopic FOXM1 transcripts in
the presence and absence of RASSF1A (left panel). Transcript levels of FOXM1 in induced conditional
RASSF1A cells ectopically expressing FOXM1 relative to FOXM1 transcript levels in non-induced
conditional cells (right panel). Mean values ± s.d. of four independent experiments are presented.
p-values < 0.05 are indicated by asterisks.
In further experiments, we found that RASSF1A suppressed ectopic expression of FOXM1
at the transcriptional level, as assessed by qPCR (Figure 3D). To rule out unspecific inhibitory
effects of RASSF1A on the promoter driving ectopic FOXM1 expression, we used two different
promoters to enforce FOXM1 expression. However, RASSF1A suppressed ectopic expression of FOXM1
independently of the promoter sequence used. This phenomenon means that it is not possible to assess
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whether ectopic FOXM1 expression can rescue cells from RASSF1A-mediated suppression of ERα
and growth arrest. Importantly, however, it indicates that RASSF1A likely affects FOXM1 transcript
stability, for example by up-regulation of inhibitory RNAs that target FOXM1 transcripts.
2.4. FOXO3A Is Required for RASSF1A-Mediated Growth Arrest
To determine whether RASSF1A also affects ERα expression and activity in breast cancer cells
through activation of FOXO3A transcriptional activity, MCF7 and T47D cells that conditionally
express RASSF1A [3] were transiently transfected with the FHRE-Luc reporter plasmid [6] that is
transcriptionally activated by the O subgroup of FOX proteins (FOXO proteins). The cells were cultured
in the presence of doxycycline to induce RASSF1A expression, or without doxycycline as a control.
After 48 h the cells were harvested, and the activity of the reporter was measured using luciferase
assays. This revealed that FOXO transcriptional activity is increased as a consequence of RASSF1A
induction (Figure 4A). No non-specific activation of the reporter construct was detected in parental
MCF7 and T47D cells upon doxycycline treatment (Figure 4A).
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Figure 4. FOXO3A is required for RASSF1A-mediated growth arrest and senescence. (A) Conditional
MCF7 (MCF7 RASSF1A tet) and T47D (T47D RASSF1A tet) cells were transfected with the FOXO
luciferase reporter plasmid FHRE luc [6]. After 24 h RASSF1A expression was induced by administration
Cancers 2020, 12, 2689 9 of 22
of 1 µg/mL doxycycline. Subsequent luciferase expression was measured 48 h later. To exclude
any unspecific activation of FOXO by doxycycline the same experimental procedure was performed
using parental MCF7 (MCF7p.) and T47D (T47Dp.) cells. Mean values ± s.d. of three independent
experiments are presented. p-values < 0.05 are indicated by asterisks. (B) Stable knockdown of FOXO3A
in conditional RASSF1A MCF7 cells using shRNA (FOXO3A k.o.1). mRNA and protein lysates from the
cell extracts were prepared 16 days after lentiviral transduction and selection with neomycin. Reduced
expression of FOXO3A in conditional RASSF1A FOXO3A k.o. cells were evidenced by quantitative
PCR (left panel) and immunoblotting using the indicated antibodies (right panel). Mean values ± s.d. of
four independent experiments are presented. p-values < 0.05 are indicated by asterisks. (C) Conditional
RASSF1A FOXO3A k.o. and negative control cells were transfected with the FHRE-Luc reporter
plasmid [6]. After 24 h RASSF1A expression was induced by administration of 1 µg/mL doxycycline.
Subsequent luciferase expression was measured 48 h later. (D) Equal numbers of conditional RASSF1A
FOXO3A k.o. and negative control cells were cultured in the presence or absence of 1µg/mL doxycycline.
After 15 days, colonies were fixed and counted at equivalent time points. Mean values ± s.d. of four
independent experiments are presented. p-values < 0.05 are indicated by asterisks. (E) Equal numbers
of conditional RASSF1A FOXO3A k.o. and control cells were cultured in the presence or absence
of 1 µg/mL doxycycline. After 6 days, colonies were fixed and counted at equivalent time points.
Mean values ± s.d. of four independent experiments are presented. p-values < 0.05 are indicated
by asterisks. (F) FOXO3A knockdown and negative control conditional RASSF1A cells were either
cultured with or without 1 µg/mL doxycycline for 48 h. Afterward cells were harvested and lysates
were analyzed by immunoblotting using the indicated antibodies. (G) Ectopic FOXO3A expressing or
empty vector-carrying conditional RASSF1A cells were established by retroviral transduction. Both cell
lines were cultured in the presence or absence of 1 µg/mL doxycycline, and lysates were analyzed by
immunoblotting using the indicated antibodies.
To investigate whether FOXO3A is responsible for RASSF1A-induced FOXO transcriptional
activity, we employed a stable knockdown of FOXO3A in the RASSF1A conditional MCF7 cells.
All shRNAs tested gave an only partial reduction of FOXO3A expression. The shRNA that generated
the strongest reduction of FOXO3A expression was used to perform functional analysis. Reduced
expression of FOXO3A was evidenced by immunoblotting and qPCR (Figure 4B). In comparison to
controls, FOXO3A knockdown substantially reduced FOXO transcriptional activity upon induction of
RASSF1A expression (Figure 4C), demonstrating that at least the majority of RASSF1A-induced FOXO
transcriptional activity is mediated by FOXO3A.
To test whether FOXO3A is important for RASSF1A-mediated growth arrest, equal numbers of
FOXO3A knockout and negative control RASSF1A conditional cells were cultured in the presence or
absence of doxycycline. Approximately two weeks later colonies were fixed and counted at equivalent
time points. Knockout cells formed more colonies than negative control cells in the presence of
RASSF1A (Figure 4D), indicating that FOXO3A is required for RASSF1A-mediated growth arrest.
To determine whether FOXO3A is also important for RASSF1A-mediated induction of senescence,
equal numbers of FOXO3A knockout and control RASSF1A conditional cells were again cultured in
the presence or absence of doxycycline. After 6 days the cells were fixed and senescent cells were
quantified. In the presence of RASSF1A, the FOXO3A knockout cells exhibited a lower percentage of
senescent cells compared to the control cells (Figure 4E), indicating that FOXO3A is also important for
RASSF1A-mediated growth arrest.
To investigate whether FOXO3A is also important for RASSF1A-mediated inhibition of ERα
and FOXM1 expression, FOXO3A knockout and negative control RASSF1A conditional cells were
cultured in the presence or absence of doxycycline. After 48 h the cells were harvested and lysates
were analyzed by immunoblotting. Partial knockdown of FOXO3A in RASSF1A conditional MCF7
cells resulted in increased levels of both ERα and FOXM1 relative to controls upon induction of
RASSF1A expression (Figure 4E), suggesting that FOXO3A knockdown abrogates RASSF1A-mediated
suppression of ERα and FOXM1 expression. Consistently, while ectopic expression of FOXO3A did
not change the expression of ERα and FOXM1 in the absence of RASSF1A, in the presence of RASSF1A
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ectopic expression of FOXO3A, augmented the reduction of ERα and FOXM1 expression (Figure 4F).
Thus, FOXM1 and FOXO3A mutually antagonize each other in a manner that is regulated by RASSF1A.
2.5. RASSF1A Increases FOXO3A Transcriptional Activity through Suppression of AKT-Mediated Inhibitory
Phosphorylation and Increased Expression of FOXO3A
AKT phosphorylates S253 and S315 of the FOXO3A protein, leading to proteasomal degradation
of FOXO3A [9]. However, in the presence of myristylated AKT1 (MyrAKT1) [35] that is
constitutively activated, we still found that RASSF1A increased FOXO transcriptional activity
(Figure 5A). Since RASSF1A inhibits AKT activity through inhibiting phosphorylation of AKT
S473 [3], we speculated that RASSF1A may increase FOXO3A transcriptional activity by suppressing
AKT-mediated phosphorylation of the FOXO3A protein. To determine whether this is the case, MCF7
cells conditional for RASSF1A expression were stably transduced with a retroviral construct that directs
inducible expression of MyrAKT1 (MyrAKT1ERtam) [36]. These cells were cultured in the presence
or absence of doxycycline. To activate the conditional MyrAKT1, 4-Hydroxytamoxifen (4-OHT) was
added. After 20 min 4-OHT induction, cells were harvested, and nuclear and cytoplasmic extracts
were prepared. Phosphorylation of AKT S473 and FOXO3A S253 was monitored by immunoblotting.
Consistent with our previous findings, RASSF1A caused decreased phosphorylation of MyrAKT1 on
S473. RASSF1A also decreased phosphorylation of FOXO3A S253 (Figure 5B). Furthermore, when
MCF7 and T47D cells conditional for RASSF1A were cultured in the presence or absence of doxycycline,
increased transcription of endogenous FOXO3A was observed upon RASSF1A induction (Figure 5C).
Collectively these findings suggest that RASSF1A increases FOXO3A transcriptional activity through
suppression of AKT-mediated inhibitory phosphorylation of the FOXO3A protein, and through
increasing transcription of FOXO3A.
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AKT- ediated inhibitory phosphorylation and increased expression of F XO3 . (A) Conditional
RASSF1A MCF7 (left panel) and conditional RASSF1A T47D cells (right panel) [3] were co-transfected
with a eukaryotic MyrAKT1 expression construct [35] and the FHRE Luc plasmid [6]. 24 h after
transfection cells were cultured in the presence or absence of 1 µg/mL doxycycline for 48 h to induce
RASSF1A expression. Subsequently, luciferase expression was analyzed. Mean values ± s.d. of four
independent experiments are presented. p-values < 0.05 are indicated by asterisks. (B) Conditional
RASSF1A MCF7 cells transduced to express MyrAKT1ERtam or empty vector were cultured in the
presence or absence of 1 µg/mL doxycycline for 48 h as indicated. To investigate the temporal influence
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of RASSF1A upon phosphorylation of MyrAKT1 and subsequent phosphorylation of FOXO3A,
conditional RASSF1A cells were cultured in the absence or presence of 1 µg/mL 4-Hydroxytamoxifen
(4-OHT) for activation of MyrAKT1 [36] as indicated. Cells were prepared 40 min after the administration
of 4-OHT. Subsequent immunoblotting of the cytoplasmic and nuclear extracts were probed with
the indicated antibodies. (C) Conditional RASSF1A MCF7 and T47D cells were cultured in the
presence or absence of 1 µg/mL doxycycline for 48 h. Afterward, cells were harvested for mRNA
preparation. Transcript levels of FOXO3A were analyzed by quantitative PCR. Mean values ± s.d. of
four independent experiments are presented. p-values < 0.05 are indicated by asterisks.
2.6. RASSF1A and FOXO3A Cause Decreased ERα and ERβ Activity
As both RASSF1A and FOXO3A inhibit expression of ERα target genes [3,21], we hypothesized
that RASSF1A may affect the transcriptional activity of ERα through increasing FOXO3A transcriptional
activity. If so, then RASSF1A expression should inhibit both ERα and ERβ, as FOXO3A suppresses both
ERα and ERβ activity [21]. As shown in Figure 6A, co-transfection of RASSF1A together with either
ERα or ERβ expression constructs [37,38] into parental MCF7 and T47D cells resulted in inhibition of
the transcriptional activity of both ERα and ERβ, as evidenced by measuring transcriptional activation
of a luciferase reporter construct (3× ERE TATA luc) [38] that is driven by tandem estrogen response
elements (EREs). Co-transfection of FOXO3A [6] together with either ERα or ERβ also inhibited the
transcriptional activity of both ERs (Figure 6B). Ectopic expression of FOXO3A in MCF7 cells did not
change ERα protein levels (Figure 6C), consistent with previous reports showing that FOXO3A inhibits
ER function without affecting their expression [21] and our own observation (Figure 4F). Based on
the results shown in Figure 4A,E,F, we conclude that RASSF1A inhibits ERα activity at least in part
through modulation of FOXO3A activity.
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(upper panel) and parental T47D cells (lower panel) were co-transfected with a RASSF1A expression
construct or empty vector together with either ERα [37] or ERβ [37] and an ER luciferase reporter
plasmid (3× ERE TATA luc) [38]. 48 h after transfection luciferase expression was measured. Mean
values ± s.d. of five independent experiments are presented. p-values < 0.05 are indicated by asterisks.
(B) Parental MCF7 cells were co-transfected with a FOXO3A expression construct [6] or empty vector
in combination with either ERα [37] or ERβ [37] and the ERE driving luciferase reporter plasmid
(3× ERE TATA luc) [38]. 48 h after transfection luciferase expression was measured. Mean values
± s.d. of five independent experiments are presented. p-values < 0.05 are indicated by asterisks.
(C) Parental MCF7 cells were transfected with a FOXO3A expression construct [6] or an empty vector.
48 h after transfection cells were harvested and lysates were analyzed by immunoblotting using the
indicated antibodies.
2.7. Neither IKKβ nor AKT1 Can Override the RASSF1A-Mediated Increase in FOXO3A Activity
FOXO3A activity and cellular localization can be regulated by an AKT-independent mechanism,
in which IkB kinase (IKKβ) phosphorylates FOXO3A, leading to ubiquitin-dependent proteasomal
degradation [11]. We, therefore, investigated whether RASSF1A increases FOXO3A transcriptional
activity even in the presence of IKKβ. To this end, we co-transfected the MCF7 and T47D cells
conditional for RASSF1A expression with the FHRE-Luc reporter plasmid [6], and either IKKβ
wildtype or IKKβ mutant constructs [39]. Transfected cells were cultured in the presence or absence
of doxycycline and harvested 48 h later. FOXO transcriptional activity in the cells was measured
using luciferase assays. This revealed increased luciferase expression upon RASSF1A induction in the
presence of all IKKβ constructs (Figure 7A,B). Co-transfection revealed that RASSF1A still increased
FOXO transcriptional activity in conditional MCF7 and T47D cells even in the presence of both
MyrAkt1 [35] and IKKβ [39] (Figure 7C,D). These findings suggest that RASSF1A activates FOXO3A
through the inhibition of several signaling cascades that block the FOXO3A function. RASSF1A
may additionally increase FOXO3A transcriptional activity through the activation of proteins that
post-transcriptionally modify and thereby activate FOXO3A.
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expression was measured at equal time points approximately 48 h after RASSF1A induction.
Mean values ± s.d. of five independent experiments are presented. P-values < 0.05 are indicated
by asterisks. (B) Conditional RASSF1A MCF7 [3] and (D) conditional RASSF1A T47D cells [3]
were co-transfected with the FOXO3A reporter plasmid FHRE-Luc [6] and IKKβ wildtype [39] in
combination with a constitutive active MyrAKT1 expression construct [35]. Increased activity of
FOXO3A in conditional MCF7 and T47D cells was still observed after RASSF1A induction, even in the
presence of both constitutive active MyrAKT1 [35] and wildtype IKKβ [39].
2.8. RASSF1A Inhibits YAP1, and Knockdown of YAP1 Suppresses Akt1 Activity, Inhibits Expression of ERα
and FOXM1, and Increases Levels of FOXO3A
RASSF1A inhibits activation of AKT1 [3,23] (Figure 5B). The mechanism through which RASSF1A
inhibits AKT1 remains to be elucidated. RASSF1A modifies the functional consequences of YAP1 [26],
a protein that activates AKT and Skp2, leading to increased degradation of FOXO1/3 [27]. We, therefore,
investigated whether RASSF1A regulates AKT1, FOXO3A, ERα, and FOXM1 through modification of
YAP1 activity.
To verify that RASSF1A affects YAP1, RASSF1A conditional cells were cultured in the presence or
absence of doxycycline. Changes in the amounts of YAP1 upon RASSF1A expression were monitored
by immunoblotting. As expected, the induction of RASSF1A expression caused decreased expression
of YAP1 protein (Figure 8A).
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in conditional RASSF1A MCF7 cells was achieved by culturing cells in the presence of 1 µg/mL
doxycycline. Cell extracts from induced and non-induced conditional RASSF1A cells were prepared
48 h after doxycycline administration and were analyzed by immunoblotting using the indicated
antibodies. Actin served as a loading control (left panel). (B) Stable knockdown of YAP1 was performed
in parental MCF7 cells using shRNAs (YAP1k.o.1 and YAP1k.o.2). Cell extracts were prepared 48 h
after lentiviral transduction. Western blots of lysates from the two independent YAP1 shRNAs
(YAP1k.o.1 and YAP1k.o.2) in MCF7 cells were probed with the indicated antibodies. Actin served as a
loading control (upper left panel). Densitometric quantification of the western blot bands scramble:
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(C) Knockdown of FOXM1 in MCF7 cells using the shRNAs FOXM1k.o.1 and FOXM1k.o.2 was
performed and mRNA was prepared 48 h after lentiviral transduction. Transcript levels of the indicated
genes were analyzed by quantitative PCR. Mean values ± s.d. of three independent experiments are
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(FOXM1k.o.1 and FOXM1k.o.2) in MCF7 cells were probed with the indicated antibodies. Actin served
as a loading control.
To determine whether loss of YAP1 expression functionally phenocopies RASSF1A expression,
we used stable knockdown of YAP1 in parental MCF7 cells. Reduced expression of YAP1 was verified
by immunoblotting (Figure 8B) and qPCR (Figure 8C). Similar to induction of RASSF1A expression,
knockdown of YAP1 caused reduced expression of ERα and FOXM1, decreased levels of pAKT S473
and increased expression of p21Cip1/Waf1 and slightly increased expression of FOXO3A (Figure 8B,C).
In contrast to knockdown of YAP1, knockdown of FOXM1 did not inhibit AKT, nor reduce levels
of pAKT S473 (Figure 8D) suggesting that RASSF1A-mediated inhibition of YAP1 is the initial step
that leads to suppression of FOXM1 and ERα expression, inhibition of AKT activity, and activation of
FOXO3A. Taken together these observations are consistent with the notion that suppression of YAP1
expression by RASSF1A plays a pivotal role in RASSF1A-induced cell cycle arrest and senescence,
and explain mechanistically how the loss of RASSF1A contributes to ERα+ breast cancer initiation
and progression.
3. Discussion
FOXM1 and FOXO3A are transcriptional regulators that play a central role during embryonic
development and adult tissue homeostasis. Deregulation of these proteins as a direct imp ct on
cancer initiation, progr ssion, and drug resistance [5]. C ntrol of th se proteins is achieved through
cell-specific expression but is ls fine-tuned by many post-translational m difications and through
interaction with specific co-factors. Besides being conv ntional transcripti n factors, they can also
function as transcriptional regulators by interacting with other tra scriptio factors d epige eti
effectors [5]. Here we sh w that the tum r suppressor RASSF1A exerts many of its effe ts through
suppression of FOXM1 and increasing FOXO3A activity. Our findings show that R SSF1A regulates
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these FOX family members at a number of levels through a complex network of molecular interactions
that includes counter-regulation of FOXM1 and FOXO3A by each other, further proteins such as AKT,
and components of the Hippo-pathway such as YAP1 (see Figure 9).
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FOXM1 expression leads to uncontrolled proliferation and resistance against senescence. (B) RASSF1A
interferes with the network outlined in (A) by inhibiting YAP1 and AKT1 signaling, thereby increasing
the activity of FOXO3A. FOXO3A can inhibit ERα and FOXM1 by two different mechanisms: (i) FOXO3A
can directly bind to the ERα and thereby inhibit its activity. This causes the suppression of ERα
target gene expression [21]. In the presence of E2, ERα binds to the FOXM1 promoter and induces
FOXM1 expression [19]. Thus, the RASSF1A-mediated increase in FOXO3A activity can suppress
FOXM1 expression through inhibition of ERα activity. (ii) FOXO3A and FOXM1 negatively regulate
each other, as FOXO3A is a functional antagonist of FOXM1 [22] and FOXM1 negatively regulates
FOXO3A [5,22]. Increased levels and activity of FOXO3A in the presence of RASSF1A, therefore, lead
to the replacement of FOXM1 on the FHRE of the FOXM1 promoter with activated FOXO3A, which
results in sustained inhibition of FOXM1 expression [22]. In addition to these FOXO3A-dependent
mechanisms, RASSF1A suppresses expression of Cdk1, 2, and Plk1 and increases expression of the
Cdk4 and 6 inhibitor p21Cip1/Waf1. As Plk1 and Cdk1, 2, 4, and 6 phosphorylate and thereby activate
FOXM1 [28–32]. RASSF1A might also inhibit FOXM1 activity by suppressing the expression of these
kinases. Taken together, these mechanisms determine that in the context of events that transform
mammary epithelial cells, RASSF1A acts as an inhibitor of ERα driven breast cancer cell growth through
a complex, hierarchical organized network that involves first suppression of the Hippo effector YAP1
and subsequent inhibition of AKT1, increased FOXO3A activity as well as the blockade of FOXM1 and
ERα expression, thereby inducing growth arrest and senescence. Based on these findings, we conclude
that loss of RASSF1A is an important initial step towards ERα+ breast cancer initiation and progression.
Our data are consistent with published observations that FOXM1 and FOXO3A have opposite roles
in cancer. Thus, while FOXM1 functions as an oncogene, FOXO3A behaves like a tumor suppressor in
most contexts [5]. Our results, therefore, suggest that RASSF1A acts as a guardian that keeps FOXM1
and FOXO3A activity and function in balance. Thus, the loss or inhibition of RASSF1A that is observed
in many types of cancer [40] would be predicted to disturb the homeostatic regulation of FOXM1 and
FOXO3A, leading to oncogenic stimulation through deregulated FOXM1 activity, which explains why
the loss of RASSF1A can contribute to cancer initiation and progression.
Our data suggest that RASSF1A can suppress FOXM1 activity at several levels. We show that
RASSF1A down-regulates FOXM1 transcription, and suggest that RASSF1A-induced FOXO3A is a
major mediator of these effects, as partial knockdown of FOXO3A abrogated RASSF1A-mediated
suppression of FOXM1 expression (Figure 8A). We also show that RASSF1A suppresses the activity
of AKT1 that can phosphorylate and inhibit the activity of FOXO3A, indicating that RASSF1A is an
activator of FOXO3A. Activated FOXO3A is a functional antagonist of FOXM1, as it replaces FOXM1 on
the FHRE of the FOXM1 promoter, leading to sustained inhibition of FOXM1 expression [22]. In addition,
RASSF1A might also suppress FOXM1 transcription by inhibiting c-Myc expression, as RASSF1A
inhibits E2-mediated expression of c-Myc [3] and FOXM1 is predicted to be a transcriptionally regulated
by c-Myc [41].
Our results also suggest that RASSF1A might up-regulate inhibitory RNAs that target FOXM1
transcripts because RASSF1A decreased levels of FOXM1 transcripts even when FOXM1 was ectopically
expressed under the control of promoters that do not contain FHRE or ERα binding elements. We note
with interest that the miRNAs miR-370 and miR-34a suppress the expression of FOXM1 [42,43].
Future research will focus on whether these or other inhibitory RNAs are up-regulated by RASSF1A.
In addition to transcriptional regulation, our results further suggest that RASSF1A may modulate
FOXM1 activity through post-translational modification. We found that RASSF1A decreased expression
of CDK1 and 2 and Plk1, which phosphorylate and thereby activate FOXM1 [5,28–32]. Furthermore,
RASSF1A up-regulated p21Cip1/Waf1 expression, which is an inhibitor of CDK4 and 6 [33]. Cdk4 and 6
stabilize and activate FOXM1, thereby maintaining the expression of G1/S phase genes and protecting
cells from senescence [32].
RASSF1A is frequently inactivated in breast carcinomas and is associated with estrogen receptor
status [3,4]. We have previously shown that RASSF1A suppresses ERα and reduces sensitivity to
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E2, leading to growth arrest and senescence [3]. FOXM1 can physiologically regulate ERα in breast
carcinoma cells [19] through activating transcription of the ERα promoter, thereby increasing ERα
expression [20]. Although FOXM1 and FOXO3A have been suggested to cooperate in the regulation of
ERα gene transcription [20], FOXO3A has been reported to inhibit ERα activity and suppresses the
outgrowth of ERα+ breast cancer [21]. This is consistent with our findings that RASSF1A counteracts
FOXM1 and upregulates FOXO3A, which would block FOXM1-dependent ERα activity, suggesting
that the effects of RASSF1A on ERα expression may be mediated at least in part by inhibition of FOXM1.
On the other hand, ERα promotes FOXM1 gene transcription in the presence of estrogens through direct
binding of ERα to an estrogen-response element site within the FOXM1 promoter [19], consistent with
our own observations (Figure 1C). Thus, an alternative mechanism may be that RASSF1A-dependent
suppression of ERα is responsible for decreased FOXM1 expression.
Knockdown of FOXM1 increased FOXO3A expression (Figure 2B), suggesting that FOXM1 can
counteract the upregulation of FOXO3A expression by RASSF1A. A number of observations suggest
that FOXM1 can also counteract RASSF1A through epigenetic mechanisms. The most prominent
mechanism by which RASSF1A expression is lost in breast and many other types of cancer is an
epigenetic modification of the RASSF1A promoter sequence [41]. Interestingly, FOXM1 itself was
shown to promote DNA methylation through increasing expression of the DNA methyltransferase
DNMT3B via the SWI/SNF2-like helicase HELLS, thereby inhibiting the expression of tumor suppressor
genes [44,45]. It is therefore highly significant that DNMTB3 is recruited to the RASSF1A promoter,
leading to hypermethylation and silencing of RASSF1A expression [46].
This study is consistent with the notion that FOXM1 and FOXO3A participate in a mutual
counterregulatory network that determines ERα expression and activity (see Figure 9). RASSF1A
maintains the balance between FOXM1 and FOXO3A under normal physiological conditions. Loss of
RASSF1A during tumorigenesis results in increased oncogenic FOXM1 activity largely due to altered
FOXO3A function resulting in increased ERα activity.
Our data suggest that activation of FOXO3A by RASSF1A is mediated by RASSF1A-dependent
suppression of AKT1 activity. They also suggest that RASSF1A counteracts AKT1 activity and thereby
activates FOXO3A through inhibition of YAP1. Consistent with this notion, RASSF1A expression in
MCF7 cells caused reduced amounts of YAP1 (Figure 8A). Furthermore, knockdown of YAP1 in MCF7
cells phenocopied the consequences of enforced RASSF1A expression, including AKT1 inhibition,
modestly increased FOXO3A levels as well as suppression of ERα and FOXM1 expression (Figure 8C).
RASSF1A activates the Hippo pathway through activating the Hippo kinases Mst1, Lat2 [47], Mst2,
and subsequent activation of Lats1 [48]. As YAP1 is a target of the Hippo pathway, RASSF1A might
suppress the growth of ERα+ breast cancer cells through activation of the Hippo kinases, leading
to inhibition of YAP1. In addition, we and others have observed that RASSF1A causes increased
phosphorylation of p38 (Supplementary information 1A) [49]. As p38 can phosphorylate FOXO3A
thereby fostering nuclear translocation and transcriptional activation of FOXO3A, we hypothesize
that RASSF1A might increase transcriptional activation of FOXO3A and thereby repress FOXM1
expression through p38. We also observed that RASSF1A decreases Plk1, another protein that inhibits
FOXO3A activity [50]. Thus, RASSF1A might additionally activate FOXO3A through inhibition of
Plk1 (Figure 1D and Supplementary information 1B).
Taken together our observations suggest that RASSF1A acts as an inhibitor of ERα driven breast
cancer cell growth through a complex, hierarchically organized network that involves first suppression
of the Hippo effector YAP1 and subsequent inhibition of AKT1, increased FOXO3A activity as well as
the blockade of FOXM1 and ERα expression, thereby inducing growth arrest and senescence. Based on
these findings, we conclude that the loss of RASSF1A is an important initial step towards ERα+ breast
cancer initiation and progression.
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4. Materials and Methods
4.1. Plasmids and Reagents
Details about the antibodies, shRNA, primer sequences, plasmids, and reagents used in this study
can be found in the Supplementary Methods File.
4.2. Cell Culture and Viral Transduction
MCF7, T47D, HEK293T, and Phoenix-GP were purchased from ATCC. Unless otherwise indicated,
the cell lines were maintained in RPMI supplemented with 10% fetal bovine serum (Takara Clontech,
Heidelberg, Germany), 1% L-glutamine, and 1% penicillin/streptomycin. The packaging cell lines
Phoenix-GP and HEK293T were used for the generation of retro-or lentiviruses following standard
calcium phosphate protocols. Cells were selected with puromycin or neomycin. For all experiments,
pooled transduced selected cell clones were used. Transduction efficiencies were monitored by flow
cytometric detection of EGFP expression.
4.3. Other Methods
Western blot analysis, FACS analysis, and clonogenic assays were performed as previously
described [3,23]. Quantitative RT-PCR was performed with Sybr Green (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’s instructions. Detailed information about all western
blotscan be found at Figures S1–S7.
4.4. Luciferase Assay Using the Dual Glow System (Promega)
The transient transfection of the FHRE luc reporter plasmid [6] was used for the analysis of FOXO
transcriptional activity. For analysis of ERα or β transcriptional activity, transient transfection of the
ER luc reporter plasmid (3× ERE TATA Luc) [38] together with either the ERα or ERβ expression
constructs [37,38] was employed (for more details see Supplementary Materials). Firefly luciferase
expression was normalized to Renilla luciferase expression according to the manufacturer’s instructions
(Promega, Heidelberg, Germany). Transfection was performed with Fugene 6 (Promega, Heidelberg,
Germany) according to the manufacturer’s instructions.
4.5. Cell Cycle Analysis
Cell cycle analysis was performed through direct DNA staining with propidium iodide (PI)
(Carl Roth GmbH, Karlsruhe, Germany). Cells were resuspended in hypotonic fluorochrome solution
(50 µg/mL PI in 0.1% sodium citrate plus 0.1% Triton X-100 (Sigma Aldrich, Taufkirchen, Germany),
then placed at 4 ◦C in the dark for 1 h before flow cytometry analysis.
4.6. Statistical Analysis
Differences between experimental groups were assessed using the Student’s t-test (Statistical
Analysis System, Release 9.3). p values < 0.05 were considered significant.
5. Conclusions
The results of this study suggest that RASSF1A suppresses ERα-driven breast carcinogenesis
through a hierarchical mechanism, in which RASSF1A represses YAP1 and subsequent inhibits AKT1
activity, resulting in increased FOXO3A activity as well as the blockade of FOXM1 and ERα expression
(see Figure 9). RASSF1A-mediated inhibition of YAP1 led to inhibition of FOXM1 through inhibition
of FOXM1 and ERα gene expression, as well as through inhibition of AKT1, which resulted in the
activation of FOXO3A and subsequent antagonism of FOXM1. Taken together, this study has delineated
the mechanistic complexity through which loss of RASSF1A serves an important initial step towards
ERα+ breast cancer initiation.
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Figure S5: RASSF1A increases FOXO3A transcriptional activity through the suppression of AKT-mediated
inhibitory phosphorylation and increased expression of FOXO3A, Figure S6: RASSF1A and FOXO3A cause
decreased ERα and ERβ activity, Figure S7: RASSF1A inhibits YAP1, and knockdown of YAP1 suppresses AKT1
activity, inhibits expression of ERα and FOXM1, and increases levels of FOXO3A.
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